查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046752

細胞激素市場－全球產業規模、佔有率、趨勢、機會和預測：按細胞激素類型、治療應用、地區和競爭格局分類，2021-2031年

Cytokine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cytokine Type, By Therapeutics Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞激素市場預計將從 2025 年的 961.1 億美元成長到 2031 年的 1,541.3 億美元，複合年成長率為 8.19%。

細胞激素，包括白細胞介素和干擾素等關鍵蛋白，作為重要的免疫調節劑，能夠精確調控細胞訊號傳導和免疫反應。推動這一市場發展的主要動力是全球慢性疾病（尤其是癌症和自體免疫疾病）盛行率的不斷上升，這導致對先進生物療法的需求日益成長。此外，細胞激素在對抗感染疾病和推動再生醫學方面的基礎應用，為市場持續成長提供了穩定的基礎，使其免受暫時性技術變革的影響。

市場概覽
預測期 2027-2031
市場規模：2025年 961.1億美元
市場規模：2031年 1541.3億美元
複合年成長率：2026-2031年 8.19%
成長最快的細分市場 癌症
最大的市場 北美洲

儘管前景光明，但由於生產和確保這些複雜生物製藥的穩定性需要耗資巨資和承擔固有的技術複雜性，該領域仍面臨著許多挑戰。鑑於需要此類醫療介入的患者群體日益成長，此經濟障礙尤為關鍵。例如，美國癌症協會預測，到2025年，光是美國就將新增約2,041,910例癌症病例，凸顯了對有效的細胞激素治療方法的迫切需求，而這種需求又需要耗費大量資源。

市場促進因素

全球細胞激素市場正受到標靶細胞激素免疫療法快速發展的推動。這些療法從根本上改變了臨床治療方法，使治療從廣譜免疫抑制轉向精準的生物干預。這一成長主要得益於新型單株抗體的創新，這些抗體能夠透過選擇性調節特定細胞激素路徑（例如白細胞介素）來有效治療複雜的自體免疫疾病，從而提高療效並降低全身毒性。細胞激素生物學研究成功轉化為商業性核准治療方法，凸顯了這項策略的有效性，並推動了持續創新。一個典型的例子是，美國食品藥物管理局 (FDA) 於 2024 年 12 月核准了高德美公司的抗 IL-31 抗體藥物 Nemulbio 用於治療異位性皮膚炎。這是一個重要的里程碑，它拓寬了患者的治療選擇，並鼓勵對雙特異性抗體等先進治療方法進行進一步研究。

同時，生物製藥公司不斷增加的研發投入為維持該市場的成長動能提供了必要的資金。大型製藥企業正積極投資其免疫學產品線，尤其是在尋求解決這些複雜蛋白質固有的生產和穩定性難題方面。這項巨額投資在行業領導企業的預算擴張中得到了清晰的體現。例如，強生公司計劃在2024年將研發支出增加約14%，投資超過170億美元以加強其治療部門，包括免疫學領域。此外，各公司正策略性地利用這些資金收購高潛力資產。例如，強生公司在2024年向Numab Therapeutics支付了12.5億美元的預付款，以獲得靶向IL-4和IL-31的雙特異性抗體的權利。這表明，前沿細胞激素介導療法具有巨大的市場價值。

市場挑戰

細胞激素生產相關的高昂成本和複雜技術難題構成了極高的經濟壁壘，直接阻礙了市場成長潛力。細胞激素是複雜的生物製藥，需要在活細胞培養中生產，因此需要高度專業的基礎設施和嚴格的穩定性評估，以防止蛋白質分解並確保療效。這些嚴苛的技術要求需要大量的資本投入和飆升的營運成本，從而構成了巨大的進入門檻，阻礙了製造商啟動新的研發專案。因此，市場正面臨治療藥物短缺的問題，難以充分滿足日益成長的強效免疫調節劑的需求。

這種固有的生產複雜性極大地限制了價格合理的治療方案的研發，導致市場競爭停滯不前。與這些技術挑戰相關的財務風險造成了後續生物製藥的嚴重短缺，而後續生物製藥對於推動市場擴張至關重要。例如，截至2025年，預計未來十年將有118種生物製藥失去專利保護，但其中只有12種分子正在研發生物類似藥。這項嚴峻的統計數據表明，約90%的相關生物製藥沒有可比較替代品，這主要是由於其巨大的生產成本和技術障礙。因此，高昂的價格居高不下，阻礙了整個產業的成長。

市場趨勢

一個重要的趨勢是將細胞激素整合到「強化型」CAR-T細胞療法中。這是一項旨在克服固態腫瘤中常見的免疫抑制微環境的關鍵創新。透過基因改造T細胞，使其僅在識別標靶抗原時才分泌促發炎細胞激素，例如白細胞介素-18 (IL-18) 和白細胞介素-7，研發人員可以增強細胞的持久性和抗腫瘤活性，而不會引起傳統靜脈注射細胞激素通常伴隨的全身毒性。這種局部給藥方法在難以用常規方法治療且標準細胞療法效果不佳的惡性腫瘤中顯示出令人鼓舞的臨床結果。例如，在一項IL-18分泌CAR-T細胞療法的I期臨床試驗中，接受常規標準治療後復發的非何傑金氏淋巴瘤患者在3個月時的總緩解率達到了80%。

同時，人工智慧（AI）在計算輔助細胞激素設計的應用正在革新下一代免疫調節劑的研發，顯著提升其穩定性並實現更精準的結合特異性。生成式AI模型使研究人員能夠設計新型蛋白質或精細改造現有細胞激素，使其選擇性地結合特定受體次單元。這種能力能夠有效分離治療效果和不良的脫靶副作用，直接解決生物製藥生產中固有的穩定性挑戰。這項技術模式轉移正吸引大量資本投資，旨在推動運算生物學平台產業化，加速開發平臺。例如，Xaira Therapeutics公司完成了資金籌措，用於建立一個結合機器學習和新型生物標靶治療藥物開發的平台。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞激素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 細胞激素類型（腫瘤壞死因子 - TNF、白細胞介素- IL、干擾素- IFN、表皮生長因子 - EGF 等）
    • 依治療目的（癌症、氣喘和氣道發炎、關節炎、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞激素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球細胞激素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16140

The Global Cytokine Market is projected for robust expansion, growing from USD 96.11 Billion in 2025 to USD 154.13 Billion by 2031, reflecting an 8.19% Compound Annual Growth Rate. Cytokines, encompassing crucial proteins like interleukins and interferons, serve as essential immunomodulating agents that meticulously regulate cellular signaling and immune responses. This market's primary impetus stems from the rising global incidence of chronic conditions, particularly cancer and autoimmune disorders, which increasingly necessitate advanced biological therapies. Moreover, the fundamental application of cytokines in addressing infectious diseases and fostering regenerative medicine provides a stable foundation for continuous market growth, independent of fleeting technological shifts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 96.11 Billion
Market Size 2031USD 154.13 Billion
CAGR 2026-20318.19%
Fastest Growing SegmentCancer
Largest MarketNorth America

Despite this promising outlook, the sector faces a significant hurdle due to the substantial costs and inherent technical complexities involved in the manufacturing and stability assurance of these intricate biologics. This economic impediment is especially pertinent given the expanding patient populations that require such medical interventions. For instance, the American Cancer Society anticipates approximately 2,041,910 new cancer diagnoses in the United States alone in 2025, underscoring the critical, yet resource-intensive, demand for effective cytokine-based treatments.

Market Driver

The Global Cytokine Market is significantly propelled by rapid advancements in targeted cytokine immunotherapies, which are fundamentally transforming clinical approaches from broad-spectrum immunosuppression to precise biologic interventions. This expansion is largely fueled by the innovation of novel monoclonal antibodies capable of selectively modulating specific cytokine pathways, such as interleukins, to effectively treat complex autoimmune conditions with enhanced therapeutic efficacy and reduced systemic toxicity. The successful progression of cytokine biology into commercially approved therapies underscores the validity of this strategy and fosters ongoing innovation, exemplified by the FDA's approval of Galderma's anti-IL-31 antibody Nemluvio in December 2024 for atopic dermatitis, a key milestone that expands patient options and stimulates further research into advanced modalities like bispecific antibodies.

Simultaneously, increasing research and development investments from biopharmaceutical enterprises are supplying the crucial capital necessary to sustain this market's growth trajectory. Major pharmaceutical corporations are actively channeling funds into their immunology pipelines, specifically targeting solutions for the manufacturing and stability challenges inherent to these complex proteins. This substantial financial commitment is evident in the escalating budgets of industry leaders; for example, Johnson & Johnson augmented its R&D spending by nearly 14% in 2024, dedicating over $17 billion to bolster its therapeutic divisions, including immunology. Furthermore, companies are strategically deploying these funds to acquire high-potential assets, as demonstrated by Johnson & Johnson's $1.25 billion upfront payment to Numab Therapeutics in 2024 for a bispecific antibody targeting IL-4 and IL-31, highlighting the significant value attributed to cutting-edge cytokine-mediated therapies.

Market Challenge

The prohibitive costs and intricate technical hurdles associated with manufacturing cytokines establish a formidable economic barrier, directly impeding the market's growth potential. As complex biologics cultivated in living cell cultures, cytokines demand highly specialized infrastructure and rigorous stability assessments to prevent protein degradation and ensure efficacy. These stringent technical requisites necessitate extensive capital investment and contribute to elevated operational expenses, thereby creating significant entry barriers that dissuade manufacturers from initiating new development programs. Consequently, the market experiences a constrained supply of therapies, struggling to adequately meet the increasing demand for potent immunomodulating agents.

This inherent manufacturing complexity substantially restricts the pipeline of affordable treatment options, leading to stagnation in market competition. The financial risks associated with these technical challenges have resulted in a notable scarcity of follow-on biologic therapies, which are crucial for driving market expansion. For instance, while 118 biologics were projected to lose patent exclusivity over the next decade as of 2025, only 12 of these molecules had biosimilars in development. This stark statistic indicates that approximately 90% of eligible biological products lack competitive alternatives, primarily due to the daunting costs and technical obstacles embedded in their production, thereby maintaining high price points and curtailing the sector's overall growth trajectory.

Market Trends

A significant trend involves the integration of cytokines into "armored" CAR-T cell therapies, a pivotal innovation aimed at overcoming the immunosuppressive microenvironment often found in solid tumors. By genetically modifying T-cells to secrete pro-inflammatory cytokines, such as interleukin-18 (IL-18) or interleukin-7, specifically upon recognizing target antigens, developers can boost cell persistence and enhance antitumor activity without triggering the systemic toxicity typically associated with conventional intravenous cytokine administration. This localized delivery approach is demonstrating encouraging clinical outcomes in malignancies that are traditionally challenging to treat and where standard cellular therapies frequently fall short, exemplified by a Phase I trial of an IL-18-secreting CAR-T therapy which showed an 80% overall response rate at three months in non-Hodgkin lymphoma patients who had relapsed after previous standard treatments.

Concurrently, the application of artificial intelligence for computational cytokine design is revolutionizing the development of next-generation immunomodulators, imbuing them with enhanced stability and precise binding specificity. Generative AI models empower researchers to engineer de novo proteins or meticulously modify existing cytokines, allowing them to selectively engage specific receptor subunits. This capability effectively separates therapeutic efficacy from undesirable off-target side effects and directly addresses the inherent stability challenges encountered in biologic manufacturing. This technological paradigm shift has attracted substantial capital investment, geared towards industrializing computational biology platforms to accelerate the development pipeline, as highlighted by Xaira Therapeutics' launch with $1 billion in committed capital to establish a platform combining machine learning with therapeutic product development for novel biological targets.

Key Market Players

  • GlaxoSmithKline PLC
  • Novartis AG
  • Amgen Inc
  • Pfizer Inc.
  • Sanofi SA
  • AstraZeneca plc
  • Biocon Limited
  • Abbvie Inc
  • Johnson and Johnson
  • UCB S.A

Report Scope

In this report, the Global Cytokine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cytokine Market, By Cytokine Type

  • Tumour Necrosis Factor-TNF
  • Interleukins-Il
  • Interferons-IFN
  • Epidermal Growth Factor-EGF
  • Other

Cytokine Market, By Therapeutics Application

  • Cancer
  • Asthma and Airway Inflammation
  • Arthritis
  • Other

Cytokine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cytokine Market.

Available Customizations:

Global Cytokine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cytokine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cytokine Type (Tumour Necrosis Factor-TNF, Interleukins-Il, Interferons-IFN, Epidermal Growth Factor-EGF, Other)
    • 5.2.2. By Therapeutics Application (Cancer, Asthma and Airway Inflammation, Arthritis, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cytokine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cytokine Type
    • 6.2.2. By Therapeutics Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cytokine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cytokine Type
        • 6.3.1.2.2. By Therapeutics Application
    • 6.3.2. Canada Cytokine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cytokine Type
        • 6.3.2.2.2. By Therapeutics Application
    • 6.3.3. Mexico Cytokine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cytokine Type
        • 6.3.3.2.2. By Therapeutics Application

7. Europe Cytokine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cytokine Type
    • 7.2.2. By Therapeutics Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cytokine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cytokine Type
        • 7.3.1.2.2. By Therapeutics Application
    • 7.3.2. France Cytokine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cytokine Type
        • 7.3.2.2.2. By Therapeutics Application
    • 7.3.3. United Kingdom Cytokine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cytokine Type
        • 7.3.3.2.2. By Therapeutics Application
    • 7.3.4. Italy Cytokine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cytokine Type
        • 7.3.4.2.2. By Therapeutics Application
    • 7.3.5. Spain Cytokine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cytokine Type
        • 7.3.5.2.2. By Therapeutics Application

8. Asia Pacific Cytokine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cytokine Type
    • 8.2.2. By Therapeutics Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cytokine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cytokine Type
        • 8.3.1.2.2. By Therapeutics Application
    • 8.3.2. India Cytokine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cytokine Type
        • 8.3.2.2.2. By Therapeutics Application
    • 8.3.3. Japan Cytokine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cytokine Type
        • 8.3.3.2.2. By Therapeutics Application
    • 8.3.4. South Korea Cytokine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cytokine Type
        • 8.3.4.2.2. By Therapeutics Application
    • 8.3.5. Australia Cytokine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cytokine Type
        • 8.3.5.2.2. By Therapeutics Application

9. Middle East & Africa Cytokine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cytokine Type
    • 9.2.2. By Therapeutics Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cytokine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cytokine Type
        • 9.3.1.2.2. By Therapeutics Application
    • 9.3.2. UAE Cytokine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cytokine Type
        • 9.3.2.2.2. By Therapeutics Application
    • 9.3.3. South Africa Cytokine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cytokine Type
        • 9.3.3.2.2. By Therapeutics Application

10. South America Cytokine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cytokine Type
    • 10.2.2. By Therapeutics Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cytokine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cytokine Type
        • 10.3.1.2.2. By Therapeutics Application
    • 10.3.2. Colombia Cytokine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cytokine Type
        • 10.3.2.2.2. By Therapeutics Application
    • 10.3.3. Argentina Cytokine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cytokine Type
        • 10.3.3.2.2. By Therapeutics Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cytokine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Amgen Inc
  • 15.4. Pfizer Inc.
  • 15.5. Sanofi SA
  • 15.6. AstraZeneca plc
  • 15.7. Biocon Limited
  • 15.8. Abbvie Inc
  • 15.9. Johnson and Johnson
  • 15.10. UCB S.A

16. Strategic Recommendations

17. About Us & Disclaimer